Virological failure in patients with HIV-1 subtype C receiving antiretroviral therapy: an analysis of a prospective national cohort in Sweden
about
No Evidence That HIV-1 Subtype C Infection Compromises the Efficacy of Tenofovir-Containing Regimens: Cohort Study in the United Kingdom.Wide variation in susceptibility of transmitted/founder HIV-1 subtype C Isolates to protease inhibitors and association with in vitro replication efficiency.Recent increased identification and transmission of HIV-1 unique recombinant forms in Sweden.Virologic outcomes in early antiretroviral treatment: HPTN 052.Increased replication capacity following evolution of PYxE insertion in Gag-p6 is associated with enhanced virulence in HIV-1 subtype C from East Africa.HIV-1 Subtype C, Tenofovir, and the Relationship With Treatment Failure and Drug Resistance"cART intensification by the HIV-1 Tat B clade vaccine: progress to phase III efficacy studies".Plasma soluble factor following two decades prolonged suppressive antiretroviral therapy in HIV-1-positive males: A cross-sectional study.Ex-vivo antiretroviral potency of newer integrase strand transfer inhibitors cabotegravir and bictegravir in HIV type 1 non-B subtypes.Phenotypic co-receptor tropism and Maraviroc sensitivity in HIV-1 subtype C from East Africa.Analyses of HIV-1 integrase sequences prior to South African national HIV-treatment program and available of integrase inhibitors in Cape Town, South Africa.Molecular Epidemiology of HIV-1 virus in Puerto Rico: Novel Cases of HIV-1 Subtype C, D and CRF-24BG.An association between K65R and HIV-1 subtype C viruses in patients treated with multiple NRTIs.Structural Implications of Genotypic Variations in HIV-1 Integrase From Diverse Subtypes
P2860
Q37365060-E7B8A43B-31D9-45FB-BBF0-38EC2BBA8484Q37454209-C2FAF6A5-6C3F-4395-A7FE-2ADF34DCDF78Q40108513-CC6FC510-E84E-466E-81DF-3571086A410DQ40254515-EEFD6A39-D9FD-4B60-8BD8-32639DAD1992Q40473808-EE358E39-6D27-402A-B6B0-92DB49D22CF0Q42380140-CC211DF7-929B-440D-A752-C46F34E7F388Q46698274-B7C9FDF7-DE05-42C3-80A3-FAAB5E8DA7D7Q47547658-A237E17D-E1FC-429B-8F4C-61C3712AAD44Q47565734-7317B9CE-BAB4-4863-B9AD-683DB83B47A8Q48102649-16DB54E0-BA1D-43DD-AEDF-E64865DCD4B3Q52352259-D763E60A-2D26-4B67-AD35-BFF9250A02F6Q52586895-50CCBC62-2876-4144-B910-48B5CB4A43BFQ55340159-9E61AEB7-78EF-4F2C-90D4-BE5B6BF8C78BQ56926444-8962E7B0-C241-4820-977B-629F95A2BF4E
P2860
Virological failure in patients with HIV-1 subtype C receiving antiretroviral therapy: an analysis of a prospective national cohort in Sweden
description
2016 nî lūn-bûn
@nan
2016 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի մարտին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Virological failure in patient ...... tive national cohort in Sweden
@ast
Virological failure in patient ...... tive national cohort in Sweden
@en
type
label
Virological failure in patient ...... tive national cohort in Sweden
@ast
Virological failure in patient ...... tive national cohort in Sweden
@en
prefLabel
Virological failure in patient ...... tive national cohort in Sweden
@ast
Virological failure in patient ...... tive national cohort in Sweden
@en
P2093
P2860
P921
P1433
P1476
Virological failure in patient ...... tive national cohort in Sweden
@en
P2093
Amanda Häggblom
Kamalendra Singh
Veronica Svedhem
P2860
P304
P356
10.1016/S2352-3018(16)00023-0
P577
2016-03-14T00:00:00Z